CLINICAL AND BIOCHEMICAL PROFILE OF STEROID-INDUCED DIABETES
Abstract
ABSTRACT
Objective: To study the clinical and biochemical profile of patients who develop steroid-induced diabetes (SID) and its predisposing factors.
Methods: Non-diabetic patients aged ≥18 years started on steroids were considered eligible for the study. In every case after detailed examination,
fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), glycated hemoglobin, fasting insulin were measured prior to starting steroids and
was repeated in 1
week (day 3/4) after starting steroid according to standard guidelines. FPG and PPG were repeated periodically during follow-up
of the patients. The utility of Indian diabetic risk score (IDRS) score in predicting the risk for SID was also assessed.
st
Result: Steroid-induced diabetes was found to be more in females than in males. IDRS is not useful in predicting the risk factors of SID. 97% of patients
had an elevation of post-prandial sugars with or without fasting hyperglycemia, but only 3% of patients had isolated elevation of fasting blood sugar.
84% of patients developed SID during the 1
week of therapy. 33% of the cases SID persisted even after 1 month of stopping steroids and on a minimal
dosage of steroids.
st
Conclusion: Unlike type 2 diabetes, there were no significant risk factors such as age, family history of diabetes to develop SID and IDRS may not be a
sensitive tool for predicting risk factors of SID. Monitoring of post-prandial sugars as compared to fasting sugars is essential for the screening of SID.
Cumulative dose of steroid may not be important to precipitate steroid diabetes.
Keywords: Glucocorticoids, Diabetes, Post-prandial glucose, Indian Diabetic Risk Score.
Downloads
References
REFERENCES
Ingle DJ. The production of glycosuria in the normal rat by means of
-hydroxy dehydroxycorticosterone. Endocrinology 1941;29:649-57.
Kim SY, Yoo CG, Lee CT, Chung HS, Kim YW, Han SK, et al.
Incidence and risk factors of steroid-induced diabetes in patients with
respiratory disease. J Korean Med Sci 2011;26(2):264-7.
Simmons LR, Molyneaux L, Yue DK, Chua EL. Steroid-induced
diabetes: Is it just unmasking of Type 2 diabetes? ISRN Endocrinol
;2012:910905.
van Raalte DH, Ouwens DM, Diamant M. Novel insights into
glucocorticoid-mediated diabetogenic effects: Towards expansion of
therapeutic options? Eur J Clin Invest 2009;39(2):81-93.
Uzu T, Harada T, Sakaguchi M, Kanasaki M, Isshiki K, Araki S, et al.
Glucocorticoid-induced diabetes mellitus: Prevalence and risk factors
in primary renal diseases. Nephron Clin Pract 2007;105(2):c54-7.
American Diabetes Association. Diabetes care. J Clin Appl Res Educ
;38:S1-93.
Arner P, Gunnarsson R, Blomdahl S, Groth CG. Some characteristics of
steroid diabetes: A study in renal-transplant recipients receiving highdose
corticosteroid therapy.
Diabetes Care 1983;6(1):23-5.
Aisen PS, Berg JD, Craft S, Peskind ER, Sano M, Teri L, et al.
Steroid-induced elevation of glucose in Alzheimer’s disease:
Relationship to gender, apolipoprotein E genotype and cognition.
Psychoneuroendocrinology 2003;28(1):113-20.
Iwamoto T, Kagawa Y, Naito Y, Kuzuhara S, Kojima M. Steroidinduced
diabetes
mellitus
and
related risk
factors in
patients with
neurologic
diseases. Pharmacotherapy 2004;24(4):508-14.
Elahi D, Muller DC, Egan JM, Andres R, Veldhuist J, Meneilly GS.
Glucose tolerance, glucose utilization and insulin secretion in ageing.
Novartis Found Symp 2002;242:222-42.
Raúl Ariza-Andraca C, Barile-Fabris LA, Frati-Munari AC, BaltazárMontufar
P.
Risk factors for steroid diabetes
in rheumatic patients.
Arch
Med
Res 1998;29(3):259-62.
Mohan V. A simplified Indian diabetes risk score for screening for
undiagnosed diabetic subjects. J Assoc Physicians India 2005;53:759-63.
Shanbhogue VV, Vidyasagar S, Madken M, Varma M, Prashant CK,
Seth P, et al. Indian diabetic risk score and its utility in steroid induced
diabetes. J Assoc Physicians India 2010;58:202.
Lieberman P, Patterson R, Kunske R. Complications of long-term
steroid therapy for asthma. J Allergy Clin Immunol 1972;49(6):329-36.
Greenstone MA, Shaw AB. Alternate day corticosteroid causes alternate
day hyperglycaemia. Postgrad Med J 1987;63(743):761-4.
Schummer BP, Parker KL. Adrenacortical steroids and their synthetic
analogs. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman
and Gilman’s Pharmacological Basis of Therapeutics. 10th ed.
New York: McGraw-Hill; 2001. p. 1655-75.
Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W,
Fuecker K, Hanefeld M. Post-challenge plasma glucose and glycemic
spikes are more strongly associated with atherosclerosis than fasting
glucose or HbA1c level. Diabetes Care 2000;23(12):1830-4.
Barrett-Connor E, Ferrara A. Isolated post-challenge hyperglycemia
and the risk of fatal cardiovascular disease in older women and men.
The Rancho Bernardo Study. Diabetes Care 1998;21(8):1236-9.
Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A.
Impaired glucose tolerance is a risk factor for cardiovascular disease,
but not impaired fasting glucose. The Funagata Diabetes Study.
Diabetes Care 1999;22(6):920-4.
Trence DL. Management of patients on chronic glucocorticoid therapy:
An endocrine perspective. Prim Care 2003;30(3):593-605.
Henriksen JE, Alford F, Ward GM, Beck-Nielsen H. Risk and
mechanism of dexamethasone-induced deterioration of glucose
tolerance in non-diabetic first-degree relatives of NIDDM patients.
Diabetologia 1997;40(12):1439-48.
Hoogwerf B, Danese RD. Drug selection and the management of
corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am
;25(3):489-505.
Agarwal PK, Jeloka T, Sharma AP. Steroid-induced diabetes mellitus
presenting as diabetic ketoacidosis. Indian J Nephrol 2002;12:122-3.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.